Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.

Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.

There is an urgent need for effective therapeutic interventions against SARS-CoV-2, including new variants that continue to arise. Neutralizing monoclonal antibodies have shown promise in clinical studies. We investigated the therapeutic efficacy of a combination of two potent monoclonal antibodies,...

Full description

Bibliographic Details
Main Authors: Koen K A Van Rompay, Katherine J Olstad, Rebecca L Sammak, Joseph Dutra, Jennifer K Watanabe, Jodie L Usachenko, Ramya Immareddy, Anil Verma, Yashavanth Shaan Lakshmanappa, Brian A Schmidt, Jamin W Roh, Sonny R Elizaldi, A Mark Allen, Frauke Muecksch, Julio C C Lorenzi, Sarah Lockwood, Rachel E Pollard, JoAnn L Yee, Peter B Nham, Amir Ardeshir, Jesse D Deere, Jean Patterson, Que Dang, Theodora Hatziioannou, Paul D Bieniasz, Smita S Iyer, Dennis J Hartigan-O'Connor, Michel C Nussenzweig, J Rachel Reader
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-07-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009688

Internet

https://doi.org/10.1371/journal.ppat.1009688

Similar Items